What do systematic reviews say?

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.15 [0.41, 3.26]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.33 [0.33, 5.45]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in cough compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.56 [0.24, 10.05]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in hyperkalaemia compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.23 [0.35, 4.4]
  2 studies · 144 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

The review found no eligible studies for this question.

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 1.02 [0.76, 1.37]
  7 studies · 2607 participants
  Low

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 3.03 [0.62, 14.93]
  4 studies · 992 participants
  Low

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 1.18 [0.85, 1.64]
  3 studies · 2252 participants
  Low

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 0.76 [0.35, 1.65]
  3 studies · 2223 participants
  Low

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 0.7 [0.49, 1.01]
  4 studies · 2321 participants
  Low

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 1.07 [0.77, 1.49]
  4 studies · 2410 participants
  Low

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Angiotensin receptor blockers (ARB) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

• Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
  RR 1.04 [0.74, 1.45]
  3 studies · 151 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to higher improvement in WHO functional class compared with placebo (high certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 8.59 [3.95, 18.72]
  4 studies · 282 participants
  High